Y-90 Radioembolization + Immunotherapy for Liver Cancer

This trial explores a new combination treatment for liver cancer that cannot be surgically removed and has spread nearby. It combines Y-90 radioembolization (a targeted radiation therapy) with three drugs: durvalumab and tremelimumab (both immunotherapy drugs) and zanzalintinib (a targeted therapy drug). The goal is to stop the cancer from growing. The trial aims to determine if this approach can effectively treat advanced liver cancer. People with liver cancer that cannot be surgically removed and who have not previously received certain treatments might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to advancements in liver cancer treatment.

The trial protocol does not specify if you must stop taking your current medications. However, certain medications like specific anticoagulants and complementary medicines must be stopped before starting the trial. It's best to discuss your current medications with the trial team to ensure safety and compliance.

Previous studies have shown that Yttrium-90 radioembolization is safe for treating liver cancer, with usually manageable side effects. Most patients tolerate this treatment well, and serious complications are rare.

Research on durvalumab and tremelimumab indicates some risk of serious side effects. About 19% of patients experienced severe reactions within six months, and fatal reactions occurred in about 8% of cases, with 1% of deaths directly linked to the treatment.

Early data suggests that Zanzalintinib is generally well tolerated. Common side effects include diarrhea and tiredness, but these are usually manageable.

Researchers are excited about this treatment combination for liver cancer because it integrates innovative methods and therapies. Unlike standard treatments like chemotherapy and surgical resection, this approach combines Y-90 radioembolization, which directly targets the liver tumors with radiation, and immunotherapy drugs like durvalumab and tremelimumab, which boost the immune system's ability to fight cancer. Additionally, zanzalintinib, a kinase inhibitor, is included to further disrupt cancer cell growth pathways. This multi-pronged strategy may offer enhanced effectiveness and a more comprehensive attack on liver cancer compared to traditional options.

This trial will evaluate a combination of treatments for liver cancer. Studies have shown that Y-90 radioembolization effectively treats advanced liver cancer, helping patients live longer and potentially making some eligible for surgery. In this trial, participants will receive Y-90 radioembolization alongside the immunotherapy treatments durvalumab and tremelimumab. Research indicates that combining durvalumab and tremelimumab can extend the lives of liver cancer patients, with some living more than five years. Additionally, zanzalintinib, another drug in this trial, has shown promise in shrinking tumors and improving survival times when used with other treatments. Together, these treatments offer hope for better outcomes for liver cancer patients.²³⁴⁵⁶